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1. Introduction
1.1. Angiogenesis in health and disease
The formation of blood vessels occurs by two mechanisms [1]: vasculogenesis and angiogen‐
esis. Vasculogenesis is the process during which blood vessels are formed de novo by in situ
differentiation of the primitive progenitor (i.e. angioblasts) into mature endothelial cells, which
was thought to take place only during embryonic development. However, angiogenesis occurs
both during embryonic development and postnatal life. Angiogenesis is defined as a process
which gives rise to new blood vessels by proliferation and migration of preexisting differen‐
tiated endothelial cells. In embryonic life, angiogenesis is a critical process that leads to
formation of stable vasculature comprised of endothelial cells, mural cells (pericytes) and
basement membrane in the adult [2]. Vasculature in healthy adult is very stable with the
exception of rare events such as cyclical growth of vessels in the ovarian corpus luteum or
during pregnancy, angiogenesis activities are rare in adult individuals [2]. In addition to
normal development, angiogenesis is known to be an important event in pathological condi‐
tions such as tissue repair during wound healing and in the growth of tumors [3].
Tumor angiogenesis, the formation of new blood vessels supplying the tumor mass, plays a
critical role in tumor growth, progression, persistence and metastasis, because the proliferation
and metastasis of malignant tumors are dependent on the sufficient nutrition supplied by the
new vessels [4-6]. Many molecules have been demonstrated as positive regulators of angio‐
genesis, including vascular endothelial growth factor (VEGF), acidic or basic fibroblast growth
factor (aFGF, bFGF), epidermal growth factor (EGF), transforming growth factor-α/β (TGF-α,
TGF-β), placental growth factor (PlGF), angiopoietin, angiogenin, endoglin (CD105), prostate-
specific membrane antigen (PSMA), the anthrax-toxin-receptor (ATR, TEM8), connective
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tissue growth factor (CTGF, CCN2), urokinase plasminogen activator (uPA), and several
others [7-10]. However, VEGF-mediated signaling through its receptor VEGFR-2 is the key
rate-limiting step in tumor angiogenesis, and plays the most important role in neovasculari‐
zation, development, and progression of various tumors including hematopoietic malignan‐
cies [11, 12], breast cancer [13], bladder cancer [14], and renal cell cancer [15]. Importantly, it
has been found that tumor growth can be attenuated via the suppression of angiogenesis [7].
1.2. Anti-angiogenic strategies for cancer treatment
Given the role of angiogenesis in tumor growth and progression, therapeutic strategies
targeting tumor vascular endothelia rather than tumor cells have several merits in comparison
to conventional anti-tumor therapies [16, 17]: (a) Vascular endothelial cells have genetically
stable MHC expression on the surface, which will not be down-regulated, in contrast to the
surface of tumor cells [18]; (b) Effector cells or antibodies can reach targeted endothelial cells
more readily than they can reach tumor cells [17]; (c) Treatment by targeting endothelial cells
is not restricted to specific tumor entities [16, 17, 19]; (d) As each tumor vessel supplies
hundreds of tumor cells, the inhibition or diminishment of a large amount of tumor cells could
be achieved merely by the comparatively limited impairment of neovascularized endothelial
cells; as a consequence, the efficiency of targeting tumor blood vessel endothelium should be
higher than that of targeting tumor cells themselves [15]. (e) Several specific anti-angiogenic
agents, such as IFN-γ, have very low toxicity in some cases of drug combination-therapy
regimens in both patients and animal models [16]. In recent years, the field of anti-angiogenic
therapy for cancers has attracted much attention. In general, anti-angiogenic strategies can be
divided into the following five categories:
1. Passive immunotherapy: The use of antibody to neutralize angiogenesis positive regula‐
tors such as VEGF. In 2003, the Food & Drug Administration (FDA) of the United States
approved Bevacizumab (Avastin®; Genentech Inc.), a humanized variant of VEGF
neutralizing monoclonal antibody, as the first anti-angiogenic agent for combinatorial
treatment with standard of care in metastatic colorectal cancer [20] and subsequently for
treatment of patients with non-small-cell lung cancer [21] or metastatic breast cancer [22].
The combinatorial treatment of Bevacizumab with conventional chemotherapy showed
increased therapeutic efficacy, for example in patients with metastatic colorectal cancer,
the median survival time was extended by 4.7 months [20]. Besides combining with
conventional chemotherapy, bevacizumab could combine with radiation therapy safely
and effectively [23].
2. Therapy with VEGF inhibitors: Since the approval of Bevacizumab in the clinical use
by  FDA,  several  VEGF  inhibitors  including  small  molecules  targeting  VEGF  or  its
receptors came into different stages of clinical development. For example VEGF-TrapR1-
R2  (Aflibercept;  Regeneron  Inc.),  a  chimeric  soluble  receptor  containing  structural
elements  from VEGFR1 and VEGFR2,  has  the  ability  to  bind to  and neutralize  the
circulating  VEGF  [24].  VEGF-TrapR1-R2  has  shown  potent  anti-tumor  activity  in
preclinical animal models and is currently in clinical trials [24]. In addition to VEGF
inhibitors,  several  small  molecule  receptor  tyrosine kinase inhibitors  (RTKIs)  target‐
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ing  VEGF  and  other  signaling  pathways  have  been  developed.  Some  of  the  most
clinically relevant RTKIs are summarized in Table 1.
Compound Company Targets Indications
Sunitinib (SU11248) Pfizer VEGFRs, PDGFRB, CSF1R, c-Kit RCC, GIST
Pazopanib (Votrient) GSK VEGFRs, PDGFRs and c-kit RCC
Sorafenib (Bay 43- 9006;
Nexavar®) Bayer
VEGFR-2 and -3, PDGFR-b, Flt-3, c-kit, Raf
kinases RCC, Inoperable HCC
Vendatanib (Caprelsa) AstraZeneca VEGFRs and EGFRs,RET- tyrosine kinases
Late-stage Medullary
Thyroid Cancer
Cabozantinib (XL184) Exelixis VEGFRs Met Prostate Cancer
Tivozanib (AV-951,
KRN-951)
AVEO
Pharmaceutical VEGFRs RCC
Axitinib (AG-013736) Pfizer VEGFRs mRCC
Linifanib (ABT-869) Abbott VEGFRs, PDGFRB, CSF1R RCC, NSCLC
Table 1. VEGF RTKIs and their indications in caner patients (adopted from [2])
3. Therapy with angiogenesis negative regulators: Many negative regulators, such as
angiostatin, endostatin, interferon-γ etc., are involved in the angiogenesis [25]. Therefore
the use of these agents to negatively regulate angiogenesis is another strategy for cancer
treatment. For example, recombinant human endostatin has been approved in September
2005 by the State Food and Drug Administration (SFDA), P. R. China. The phase III clinical
trial of endostatin in China showed promising effects. Combination of endostatin and NP
regimen (vinorelbine and cisplatin) significantly improved the therapeutic efficacy in
patients with advanced nonsmall-cell lung cancer and safely extended the median time
of tumor progression [26].
4. Therapy with vascular disrupting agents: A strategy directly induce vascular collapse.
ASA404, a flavonoid compound, is one of the vascular disrupting agents that induce
apoptosis of tumor associated endothelial cells, resulting in the inhibition of blood flow,
causing hypoxia and necrosis in tumor mass. ASA404 is currently in advanced stage of
clinical trial in combination with standard of care in non-small-cell lung cancer [27].
5. Active immunotherapy: Active immunotherapy targeting tumor angiogenesis is a novel
modality for treatment of cancers which is based on several assumptions: a) Tumor-
derived endothelial cells (ECs) possess characteristics distinct from those of normal tissue
[18]. b) Specific immune responses against self-antigen can be elicited. c) Tumor growth
can be attenuated via suppression of angiogenesis [7]. The main aim of the active immu‐
notherapy targeting tumor vessels is to break self immunological tolerance to the positive
regulators of angiogenesis, hereby inhibiting tumor angiogenesis and thus leading to the
inhibition of tumor growth and metastasis. Anti-angiogenic active immunotherapies can
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be divided into two categories: one is based on the immunological cross-reactions
mediated by vaccination with xenogeneic homologous molecules associated with
angiogenesis, and the other targets non-xenogeneic homologous molecules. Therapeutic
targets, vaccines and tumor models used in anti-angiogenic active immunotherapy for
cancers are summarized in Table 2.
Strategies Therapeutic targets Vaccines Tumor models References
Vaccination based
on xenogeneic
homologous
molecules
Murine vascular
endothelial cells
Human umbilical vein endothelial
cells, human dermal microvascular
endothelial cells, and bovine
glomerular endothelial cells
Meth A, H22,
MA782/5S, FM3A, and
Lewis Lung carcinoma
29
Murine VEGF Recombinant plasmid encoding
VEGF of xenopus laevis
Meth A, H22 and
MA782/5S
32
pMAE5△5 vectors harboring
human VEGF 121 gene and
mutated human VEGF 121 gene
EL-4, B16, and TC-1 33
Canine VEGF Liposome-DNA adjuvant Soft tissue sarcoma 34
Murine VEGFR-2 Plasmid DNA encoding quail
VEGFR-2
Meth A, EL-4 and
MOPC-315,
36
Plasmid DNA encoding the C
terminal 37 amino acids of hCGβ,
5 different CTL epitopes from
human surviving and the 3rd and
4th extracellular domains of
VEGFR-2
LL/2 lung carcinoma 37
Bifidobacterium infantis expressing
human sKDR
Lewis lung cancer 38
Murine FGFR-1 cDNA encoding Xenopus FGFR-1 Meth A, H22, and
MA782/5S
41
Murine αvβ3 Plasmid DNA encoding the ligand-
binding domain of chicken
integrin β3
Meth A, H22, and
MA782/5S
43
Murine MMP-2 Plasmid DNA encoding chicken
MMP-2
LL/2, Meth A, H22 48
Murine RHAMM Plasmid encoding Xenopus
RHAMM
B16 49
Murine DLL4 Plasmid encoding human DLL4 D2F2/E2 55
Murine Angiomotin Plasmid encoding human
angiomotin
TUBO breast cancer 57, 61
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Strategies Therapeutic targets Vaccines Tumor models References
Vaccination based
on non-xenogeneic
homologous
molecules
Murine VEGFR-2 flk-1 protein pulsed DC B16, 3LL 62
flk1 mRNA-transfected DC B16, MBT-2 64
Murine sVEGFR-2 and IFN-γ fusion
gene-transfected DC
B16, 3LL 68
Recombinant plasmid encoding
flk-1
B16, MC38, D121 63
H-2Db-restricted KDR2 or KDR3
peptide
MC38 69
L. monocytogene-based Flk-1 4T1-Luc 71, 72
pSG.SS.Flk-1ECD.C3d3 BTT739 73
VEGFR-2 in transgenic
mice expressing HLA-
A*0201
HLA-A*0201-restricted VEGFR-2
epitope peptide
MC38, B16 70
Human VEGFR-2 HLA-A*2402-restricted
VEGFR2-169
Patients with advanced
pancreatic cancer
74
Murine FGF-2 FGF-2 heparin-binding structural
domain peptide
B16BL6, LLC-LM 39
Murine EGFR Recombinant mouse EGFR
ectodomain pulsed DC
Lewis lung carcinoma
and mammary cancer
80
Legumain Minigene plasmid DNA encoding
murine MHC class I antigen
epitopes of Legumain
D2F2 85
Endoglin Plasmid DNA encoding murine
endoglin
D2F2 86
Listeria-based vaccines encoding
murine endoglin
4T1-Luc and NT-2
breast cancer
87
Endothelium Endothelium lysates pulsed DC Colon-26 colon cancer 89
Glutaraldehyde-fixed HUVECs Patients with recurrent
malignant brain
tumour or metastatic
colorectal cancer
90
Notes: B16: B16 melanoma; B16BL6: B16BL6 tumor cells; D121: D121 lung carcinoma; D2F2: breast carcinoma cells; 
D2F2/E2: mammary tumor cells derived from BALB/c mouse and were transfected with the cDNA encoding ERBB2; 
EL-4: EL-4 lymphoma; FM3A: mammary cancer; H22: H22 hepatoma; LL/2: LL/2 Lewis lung carcinoma; LLC-LM: LLC-
LM tumor cells; MA782/5S: MA782/5S mammary cancer; Meth A: Meth A fibrosarcoma; MBT-2: MBT-2 bladder tu‐
mor; MC38: MC38 murine colon cancer; MOPC-315: MOPC-315 plasmacytoma; TC-1: TC-1 carcinoma; 3LL: 3LL Lewis 
lung carcinoma; HUVECs: human umbilical vein endothelial cells.
Table 2. Anti-angiogenic active immunotherapy for cancers
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2. Anti-angiogenic active immunotherapy
2.1. Anti-angiogenic active immunotherapy based on xenogeneic homologous molecules
Homologous molecules in different species are formed as the result of evolution. Molecules
with essential functions keep the stability of their molecular sequences, although some
moderate degree of evolution is essential for adaptation to different environments and
physiological requirements in different species. Many genes in the human and mouse genome
are similar (but not identical) to the corresponding genome sequences of the fruit fly Droso‐
phila melanogaster and other non-vertebrates such as Xenopus laevis [28]. In consequence,
effective immune response to self antigens associated with angiogenesis can thus be induced
by vaccination with xenogeneic homologous molecules.
2.1.1. Cell vaccine
Neovascular endothelial cells in tumor tissues express proteins not present or not detectable
in normal vascular endothelial cells, such as αvβ3 integrin and receptors for certain angiogenic
growth factors [18]. These proteins in murine vascular endothelial cells share homology to
varying degree with counterparts of other species including human [18]. Vaccination of mice
with paraformaldehyde-fixed xenogeneic human and bovine proliferative vascular endothe‐
lial cells, such as human umbilical vein endothelial cells, human dermal microvascular
endothelial cells, and bovine glomerular endothelial cells, resulted in successful breaking of
the immunological tolerance to autogeneic vascular endothelial cells in several murine tumor
models, such as Meth A fibrosarcoma, MA782/5S and FM3A mammary cancer, H22 hepatoma,
and Lewis lung carcinoma, generating a protective and therapeutic anti-tumor immunological
reaction [29]. Antibodies against the receptors associated with tumor angiogenesis generated
in mice immunized with the xenogeneic homologous proliferative vascular endothelial cell
vaccines might inhibit the proliferation of endothelial cells in vivo, leading to the regression
of established tumor, and the prolonged survival of tumor-bearing mice [29]. Tumor angio‐
genesis could be suppressed by the adoptive transfer of autoreactive immunoglobulins
purified from the immunized mouse, resulting in inhibition of tumor growth in mice [29].
Autoantibody sediments were detected on ECs within tumor tissues in the immunized mice
by immunohistochemical analysis [29]. Furthermore, Western blot analysis showed that
reactions between the extract from murine ECs and the serum from the immunized mice
resulted in several positive bands, at least two of which, with the molecular weight of 220 kDa
and 130 kDa, had similar molecular sizes to those of ligand-binding sites of known VEGFR2
and αv integrin, respectively [29], although the authors did not provide direct evidence to
demonstrate that the two positive bands aforementioned contained VEGFR2 and αv integrin
respectively. Immune cell subset depletion experiments showed that the production of
autoantibodies against tumor vascular ECs and the anti-tumor effect were dependent on
CD4+ T lymphocytes [29].
In 2006, early-outgrowth progenitor endothelial cells (EO-EPCs) have been characterized on
the basis of their dendritic-like phenotypes (such as expression of HLA-DR, CD40, CD54,
CD80, and CD86), phagocytotic and antigen-presenting functions, and endothelial markers
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(such as VEGER2, von Willebrand factor, CD105) [30]. EO-EPCs also incorporated DiLDL and
bound UEA-I, which are endothelial features, and additionally, they formed vascular-like
structures on Matrigel [30]. Thus, it might be a promising strategy toward anti-angiogenic
cancer treatment to use EO-EPCs as cell vaccine to inhibit tumor angiogenesis, since such cells
might function both as dendritic-like cells to augment anti-tumor immunity and as xenogeneic
proliferative endothelial cells to break self-tolerance, thereby inducing profound anti-angio‐
genic effects in vivo.
2.1.2. Non-cell vaccines
2.1.2.1. VEGF/VEGFR2
VEGF is a potent and crucial vasculogenic and angiogenic factor, which can induce endothelial
cell proliferation, promote cell migration, and inhibit endothelial cell apoptosis [5, 6]. In most
types of cancers, VEGF is often present at elevated levels, and strategies aimed at blocking its
activity usually lead to suppression of tumor angiogenesis and consequently tumor growth
inhibition [31]. The amino acid sequence of VEGF in Xenopus laevis shares 75 % and 73 %
homology with that of VEGF164 in mice and that of VEGF165 in humans, respectively [32].
Recombinant eukaryotic expression plasmids harboring VEGF-encoding gene of mice and
Xenopus laevis, respectively, designated as MVEGF-P and XVEGF-P, have been constructed.
Immunization of mice with XVEGF-P provoked protective and therapeutic anti-tumor
immunological effects in mouse tumor models with Meth A fibrosarcoma, MA782/5S mam‐
mary cancer and H22 hepatoma [32]. Anti-VEGF specific autoantibody was detected in serum
of mice vaccinated with XVEGF-P by Western blot and ELISA [32]. The VEGF levels in the
tumor-bearing mice immunized with XVEGF-P was lower than that in the control groups [32].
Furthermore, the frequency of anti-VEGF antibody-producing B cells in the spleen of mice
immunized with XVEGF-P was remarkably higher than that in the spleen of control groups
where such B cells were undetectable [32]. VEGF-mediated proliferation of ECs could be
inhibited in vitro by purified immunoglobulins from XVEGF-P-immunized mice. Adoptive
transfer of the purified immunoglobulins into non-immunized tumor-bearing mice could also
inhibit tumor angiogenesis in vivo and generate anti-tumor effects [32]. Anti-CD4+ monoclonal
antibody could obstruct the escalation of concentration of immunoglobulin IgG1 and IgG2 in
serum and also block the anti-tumor effects of XVEGF-P DNA vaccines, indicating that CD4+
T lymphocytes were responsible for XVEGF-P-induced anti-tumor effects [32]. The possibility
that the anti-tumor activity may result from nonspecifically augmented immune response
could be ruled out by the findings that no increase in NK activity of spleen cells or in the level
of cytokines such as IFN-α, IFN-β, TNF-α, or β-chemokine in sera was found in immunized
mice [32]. Recently, it was reported that when immunized with human VEGF isoform 121 gene
(hVEGF121) inserted into pMAE5△5 vector (pM-VEGF) and later challenged with melanoma
or lung carcinoma tumor cells, a reduction of tumor growth and an increased survival of
tumor-bearing C57BL/6 mice were observed because the hVEGF121 gene is highly homolo‐
gous to its murine counterpart [33]. A decrease in tumor cell density around vessels and in
mitotic figures, as well as an increase in apoptotic tumor cells were manifested by histopatho‐
logical analyses of tumors from C57BL/6 mice immunized with hVEGF121 [33]. Spleen cells
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from mice immunized with pM-VEGF showed a significant enhanced cytotoxic activity against
VEGF-secreting tumor cells, including EL-4 lymphoma, B16-F10 melanoma, and TC-1
carcinoma, as compared with those obtained from the mice immunized with the pMAE5△5
‘‘empty’’ vector [33]. IFN-γ ELISPOT assay revealed a significant increase in the number of
spots in spleen cells from mice immunized with pM-VEGF [33]. Vaccination with a mutated
hVEGF121 gene inserted into the pMAE5△5 vector (pM-VEGFmut) produced similar in vitro
and in vivo results, and remarkably reduced the number of spontaneous metastases in a murine
model with Lewis lung carcinoma [33]. Serum VEGF levels decreased 8-fold in mice vaccinated
with pM-VEGF or pM-VEGFmut as compared with those in pMAE5△5 treated mice [33]. A
significant correlation was also found between the elevation of serum VEGF level and the
increase of the tumor dimensions [33]. However, antibody responses against the
GSThVEGF121 fusion protein or GST alone used as capture antigens in ELISA were undetect‐
able in animals vaccinated with pM-VEGF or pM-VEGFmut [33]. These findings indicate that
human VEGF-harboring DNA vaccine can be employed for anti-angiogenic active immuno‐
therapy for cancers in mice and direct cell cytotoxicity contributes to the overall anti-tumor
effects observed in immunized mice [33].
Previous studies in rodent tumor models have indicated that immunization against xenogeneic
growth factors is more likely to induce effective anti-tumor responses than immunization
against the syngeneic growth factor [34]. In 2007, an investigation was conducted to assess the
safety and anti-tumor and anti-angiogenic effects of a xenogeneic VEGF vaccine in pet dogs
with spontaneous cancer. Nine dogs with soft tissue sarcoma were immunized with a
recombinant human VEGF vaccine over a 16-week period [34]. The xenogeneic VEGF vaccine
was well-tolerated by all dogs and resulted in induction of humoral responses against both
human and canine VEGF in animals that remained in the study long enough to receive multiple
immunizations [34]. Three of five multiply immunized dogs also experienced sustained
decreases in circulating plasma VEGF concentrations and two dogs had a significant decrease
in tumor microvessel density [34]. The overall tumor response (>50% decrease in tumor
volume) rate was 30% for all treated dogs in the study. Thus, it was concluded that a xenogeneic
VEGF vaccine may be a safe and effective alternative means of controlling tumor growth and
angiogenesis [34].
VEGF receptor-2 (VEGFR-2, also known as fetal liver kinse-1 (flk-1) in mouse and kinase-
containing  domain  receptor  (KDR)  in  human)  is  the  main  receptor  responsible  for  the
VEGF-mediated angiogenic  activity  [6].  The  impairment  of  vasculogenesis  and death  of
embryo at day 8.5 were observed as the result of the targeted inactivation of flk-1 gene in
mice [35]. Overexpression of KDR was found on activated endothelial cells of newly formed
vessels [6]. It was discovered that the primary sequence of quail VEGFR-2 (qVEGFR-2) was
67% and 70% identical at the amino acid level with mouse and human homologues (flk-1
and KDR), respectively [36].  Immunotherapy with a vaccine based on quail homologous
VEGFR-2  elicited  protective  and  therapeutic  anti-tumor  immunity  in  both  solid  and
hematopoietic  tumor  models  in  mice,  such  as  LL/2  Lewis  lung  carcinoma,  CT26  colon
carcinoma,  Meth  A  fibrosarcoma,  MOPC-315  plasmacytoma,  and  EL-4  lymphoma  [36].
Autoantibodies against flk-1 in the immunized mice were identified. Sera from qVEGFR-2-
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immunized mice recognized not only recombinant qVEGFR-2, but also recombinant mouse
VEGFR-2  (mVEGFR)  in  Western  blot  analysis  [36].  In  contrast,  the  sera  isolated  from
controls  showed  negative  staining  [36].  Sera  from  mice  immunized  with  qVEGFR-2
recognized  a  single  band  in  flk-1-positive  mouse  SVEC4-10  endothelial  cells  and  KDR-
positive  human  umbilical  vein  endothelial  cells,  with  the  same  size  as  recognized  by
commercially available flk-1 or KDR antibodies [36]. Sera from qVEGFR-2-immunized mice
also recognized recombinant protein qVEGFR-2 and mVEGFR-2 in ELISA [36]. Detectable
IgG1  and  IgG2b  with  significantly  elevated  concentration  in  sera  were  found  to  be
responsible  for  the  immunoglobulin  response  to  VEGFR-2  [36].  Anti-VEGFR-2  specific
antibody-producing  B  cells  were  detected  by  ELISPOT.  The  number  of  anti-VEGFR-2
antibody-producing B cells was elevated in the spleens of mice immunized with qVEGFR-2,
compared with that in controls [36].  Deposition of immunoglobulins on endothelial cells
was  found within  tumors  from qVEGFR-2-immunized mice,  but  not  from controls  [36].
Adoptive  transfer  of  the  purified  immunoglobulins  from  qVEGFR-2-immunized  mice
resulted  in  inhibition  of  VEGF-mediated  endothelial  cell  proliferation  and  effective
protection against tumor growth [36]. Angiogenesis was markedly suppressed within the
tumors, and the vascularization of alginate beads was also diminished [36]. Depletion of
CD4+ T lymphocyte could abrogate the anti-tumor activity and the production of autoanti‐
bodies against flk-1 [36].
Very recently, a DNA vaccine designed by synergizing different tumor antigens with VEGFR2
was constructed. A DNA fragment (HSV) encoding the C terminal 37 amino acids of human
chorionic gonadotropin β chain (hCGβ), 5 different HLA-restricted cytotoxic T lymphocyte
epitopes from human survivin and the third and fourth extracellular domains of VEGFR2 was
inserted into the sequence between the luminal and transmembrane domain of human
lysosome-associated membrane protein-1 cDNA for the construction of a novel DNA vaccine
(p-L/HSV) [37]. Vaccination of the mice with p-L/HSV elicited potent and long-lasting cellular
and humoral immune responses to the specific antigens and showed a prominent anti-tumor
effect on the LL/2 lung carcinoma model in syngeneic C57BL/6 mice. In addition, the tumor
vasculature was abrogated as observed by immunohistochemistry in p-L/HSV immunized
mice [37]. These data indicates that the strategies of combining anti-tumor with anti-angio‐
genesis cooperate well. Such a study may shed new light on the designing of vaccine for cancer
in the future.
Again in 2012, a Bifidobacterium infantis-based vaccine that express human extracellular domain
of VEGFR2 (sKDR) was established [38]. Immunization of the mice with the Bifidobacterium
infantis-based vaccine through caudal vein could significantly suppress the tumor growth and
prolong the survival of the tumor-bearing mice. On the other hand, this immunization strategy
could significantly increase the tumor necrosis, and obviously decrease microvessel density
and the blood flow signals in tumor [38].
2.1.2.2. FGFR-1
Fibroblast growth factor receptor-1 (FGFR-1) is expressed on endothelial cells and many types
of tumors [39, 40]. The Xenopus homologue of FGFR-1 is 80% and 74% identical at the amino
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acid level with mouse FGFR-1 and human FGFR-1, respectively [41]. Therefore, FGFR-1 may
be used as another ideal target for anti-angiogenesis therapy. Vaccination with Xenopus
FGFR-1 (pxFR1) provoked protective and therapeutic effects in three murine tumor models,
including Meth A fibrosarcoma cells, H22 hepatoma cells, and MA782/5S mammary carcinoma
[41]. FGFR-1-specific autoantibodies were detected in sera of pxFR1-immunized mice by
Western blot analysis, and the purified immunoglobulins effectively inhibited endothelial cell
proliferation in vitro [41]. However, the immunoglobulins had no direct inhibitory effect on
the proliferation of above three tumor cell lines [41]. Adoptive transfer of sera or purified
immunoglobulin isolated from pxFR1-immunized mice into unimmunized mice provided
effective protection against tumor growth, while adsorption of sera or immunoglobulin with
FGFR-1-positive endothelial cells before adoptive transfer could abrogate its anti-tumor
activity [41]. Autoantibodies deposited on the endothelial cells within tumor tissues and
significantly suppressed intratumoral angiogenesis were found in pxFR1-immunized mice by
histological examination [41]. Furthermore, this anti-tumor activity and production of FGFR-1-
specific autoantibodies were abrogated by depletion of CD4+ T lymphocytes, again pointing
to their essential helper function for antibody production [41].
2.1.2.3. Integrins
Integrins are heterodimeric transmembrane proteins consisting of α and β subunits with large
extracellular domain and short cytoplasmic tail. They play very crucial roles in angiogenesis
as the migration of endothelial cells is dependent on their adhesion to extracellular matrix
proteins such as vitronectin [42]. αvβ3 is not generally found on blood vessels in normal tissues,
but its expression is enhanced on newly developing blood vessels in human wound tissue,
tumors, diabetic retinopathy, macular degeneration and rheumatoid arthritis, which implies
that this integrin may play an important role in angiogenesis and development of neovascu‐
larization [42]. This distributive characteristic also makes αvβ3 an attractive target for tumor
therapy [42]. A plasmid DNA encoding the ligand-binding domain of chicken integrin β3 was
constructed to test this assumption. Immunization with chicken homologous integrin β3-based
vaccine could elicit both protective and therapeutic anti-tumor immunity in murine tumor
models with Meth A fibrosarcoma, H22 hepatoma, or MA782/5S mammary carcinoma [43].
Autoantibodies against integrin β3 in sera of the immunized mice were found by Western blot
analysis and ELISA [43]. The purified immunoglobulins could effectively inhibit endothelial
cell proliferation in vitro, and adoptive transfer of the purified immunoglobulins into non-
immunized mice could provide effective protection against tumor growth and markedly
inhibit tumor angiogenesis [43]. The anti-tumor activity and the production of integrin β3-
specific autoantibodies were CD4+ T lymphocyte-dependent [43].
2.1.2.4. MMP
Angiogenesis is an invasive process, requiring proteolysis of the extracellular matrix [44].
Inappropriate destruction of extracellular matrix components is involved in certain patholog‐
ical conditions, including arteriosclerosis, rheumatoid arthritis, and tumor aggression and
metastasis [44]. The matrix metalloproteinases (MMPs), a family of extracellular endopepti‐
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dases, can selectively degrade components of the extracellular matrix [44]. In vivo, elevated
stromal MMP-2 and MMP-9 activity is highly correlated with increased metastatic potential
in most malignant tumors [45]. Increased activity of MMPs appears to permit the tumor to
remodel its surrounding microenvironment, to grow in a permissive space, and to promote
the development of supporting stroma, including angiogenesis [46]. Moreover, numerous
pathological and clinical studies demonstrated that the MMPs were frequently overexpressed
in various solid tumor cells and peritumoral stromal cells [46]. It was reported that the
abrogation of MMP-2 alone resulted in the inhibition of the transition from the prevascular to
the vascular stage during tumor development and then of tumor growth [47]. Furthermore,
the suppression of tumor-induced angiogenesis and of invasion and metastasis of tumor cells
could be observed in MMP-2-deficient mice [47]. These findings indicated that MMP-2 alone
played an important role in angiogenesis and tumor growth. Sequence comparison analysis
showed that the primary sequence of mouse MMP-2 at the amino acid level was 82% and 91%
identical with chicken and human homologues, respectively [48]. It was reported that the
plasmid DNA vaccination with chicken homologous MMP-2 (c-MMP-2)-based model antigen
could induce both protective and therapeutic anti-tumor immunity in murine tumor models
with LL/2 Lewis lung carcinoma, Meth A fibrosarcoma, and H22 hepatoma [48]. The elevation
of MMP-2 in the sera of tumor-bearing mice was abrogated with the vaccination of c-MMP-2
[48]. The autoimmune response against MMP-2 may be provoked in a cross-reaction by the
immunization with c-MMP-2, and the autoantibody targeting to MMP-2 was elevated and
probably responsible for the anti-tumor activity [48]. Moreover, gelatinase activity of MMP-2,
including both latent MMP-2 and active MMP-2, derived from the above mentioned three
murine tumor models was apparently inhibited by the vaccination with c-MMP-2 [48].
However, the vaccination did not inhibit the gelatinase activity of MMP-9 [48]. These findings
indicate that the activity of MMP-2 is impaired by immunization with c-MMP-2 in mice.
Angiogenesis was apparently inhibited within tumors in immunized mice. The anti-tumor
activity and production of auto-antibodies against MMP-2 were abrogated by depletion of
CD4+ T lymphocytes [48].
2.1.2.5. xRHAMM
In 2010, Yang et al. [49] used a cross-reactive serological expression cloning (SEREX) strategy
(CR-SEREX) to identify novel xenogenic angiogenesis- and tumor-associated antigens in
oocytes of Xenopus laevis and found that Xenopus receptor for hyaluronic-acid-mediated
motility (xRHAMM) was the most frequently clone among 78 CR-SEREX positive clones,
suggesting that xRHAMM has the strongest immunogenic potential for xenogenic immuno‐
therapy. It was demonstrated that expression of RHAMM is restricted to the testis, thymus,
placenta, vascular endothelial cells, and various cancer cells, and RHAMM functions in
vascular endothelial cell migration, angiogenesis, and in hyaluronic-acid-induced cell mobility
[50]. In order to examine the anti-angiogenic effects, a DNA vaccine based on xRHAMM
(pcDNA3.1-xRHAMM) was constructed [49]. Intramuscular vaccination of the cationic
liposome encapsulated pcDNA3.1-xRHAMM DNA effectively induced a protective anti-
tumor immunity against local tumor and lung metastasis in B16 melanoma mouse models.
Angiogenesis was inhibited and cell apoptosis was increased within tumors. Anti-tumor
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activity of xRHAMM was mediated by both the antigen-specific cellular and humoral
responses against RHAMM, as confirmed by the depletion of immune cell subsets in vivo.
Furthermore, the anti-angiogenic and anti-tumor effects induced by vaccination of pcDNA3.1-
xRHAMM were significantly stronger than that induced by vaccination of the corresponding
autologous counterpart pcDNA3.1-mRHAMM [49].
2.1.2.6. DLL4
Notch signaling has recently emerged as a critical regulator of developmental and tumor
angiogenesis. Notch signaling in both endothelial and smooth muscle cells appears to provide
critical regulatory information to these cells downstream of the initiating signal induced by
VEGF [51, 52]. Studies in humans and mice have demonstrated that Notch ligand delta-like 4
(DLL4) is strongly expressed by the tumor vasculature and generally not by the tumor cells
themselves. In various mouse models, strong DLL4 expression was observed in the majority
of tumor vessels, contrasting with significantly lower vascular expression in adjacent normal
tissues [51]. In humans, DLL4 expression was analyzed in tumors from kidney, bladder, colon,
brain and breast [53, 54]. Robust DLL4 expression was observed specifically in the tumor
vasculature in all of these tumor types, whereas DLL4 expression was low to undetectable in
the vasculature of adjacent normal tissue. Furthermore, at least in the case of breast cancer, the
degree of DLL4 expression correlated with outcome: tumors with high DLL4 in the vasculature
progressed more rapidly [54]. These findings suggest that DLL4 is an attractive new thera‐
peutic anti-angiogenesis target. To generate the DLL4 plasmid vaccine, the cDNA encoding
human DLL4 was cloned into the pVAX1 expression vector (DLL4 vaccine), which is
specifically designed for the development of DNA vaccines and approved for use in humans.
Immunization of Balb/c mice with DLL4 vaccine could bring about a break in tolerance against
the self-antigen, DLL4. Readily detectable titers of serum antibodies against DLL4 were
induced. Moreover, immunization with DLL4-encoding plasmid DNA severely retarded the
growth of orthotopically implanted D2F2/E2 mammary carcinomas in mice by induction of a
non-productive angiogenic response. In addition to the promising therapeutic effects, no
evidence for a delayed wound healing response, or for toxicity associated with pharmacolog‐
ical blockade of DLL4 signaling, was observed in mice immunized with the DLL4 vaccine [55].
2.1.2.7. Angiomotin
Angiomotin (Amot), one of angiostatin receptors [56], is a membrane-associated protein
present on the endothelial cell surface of angiogenic tissues [57] characterized by conserved
coiledcoil and carboxy termini-PDZ domains [58]. A shorter Amot isoform (p80) confers a
hyper-migratory and invasive phenotype in transfected cells [59] and induces endothelial cell
migration during angiogenesis [60]. The longer (p130) isoform localizes to tight junctions,
regulates cell shape and appears to play a role in the later phase of angiogenesis [60]. It was
demonstrated that increased Amot expression on tumor endothelia concomitant with the
progression from pre-neoplastic lesions to full-fledged carcinoma, therefore, plasmid vaccine
encoding human p80 Amot (pAmot) was constructed [57]. Immunization of mice with pAmot
can overcome immune tolerance and induce a significant antibody response that mimic the
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effect of angiostatin. These antibodies inhibit endothelial cell migration, block tumor cell- and
bFGF-induced angiogenesis in the matrigel plug assay and prevent growth of transplanted
tumors without impairing normal stromal or retina vessels [57]. Very recently, Arigoni et al.
further showed that the pAmot-induced antibodies alter tumor vessel permeability and
structure. These combined effects of vaccine-induced anti-Amot antibodies lead to inhibition
of established clinically evident mammary tumors, massive tumor perivascular necrosis, and
an effective tumor antigen presentation in a form of epitope spreading that induces an immune
response against other oncoantigens overexpressed by tumor cells [61]. Greater tumor vessel
permeability also markedly boosts the local accumulation of doxorubicin and enhances the
anti-tumor effect of the drugs [61]. These data provide a rationale for the development of fresh
anticancer treatments based on anti-Amot vaccination in conjunction with chemotherapy
regimens.
Taken together, it is obvious that vaccination with xenogeneic homologous molecules associ‐
ated with angiogenesis, such as pro-angiogenic factors, integrins, MMP, could induce anti-
tumor immunity and thus might be a feasible strategy for cancer therapy with potential clinical
applications.
2.2. Anti-angiogenic active immunotherapies based on non-xenogeneic homologous
molecules
Given that vaccination with xenogeneic homologous molecules associated with tumor
angiogenesis could effectively induce anti-tumor immunity, it can be assumed that vaccines
based on non-xenogeneic homologous molecules, such as allogeneic homologues of some pro-
angiogenic factors or other important molecules associated with angiogenesis, could also
successfully induce specific and potent anti-tumor immunity. To date, several vaccines based
on non-xenogeneic homologous molecules were used in anti-angiogenic active immunother‐
apy for tumors.
2.2.1. VEGFR-2
As has been discussed above, VEGF-mediated signaling pathway through VEGFR-2 is a rate-
limiting step during tumor angiogenesis. Thus, VEGF/VEGFR-2 is still an ideal target in the
non-xenogeneic homologous molecules-based anti-angiogenic strategy. Immunization of mice
with VEGF receptor-2 (flk-1)-pulsed dendritic cells (DC) can break self-tolerance to VEGFR-2,
induce CTL and antibody responses to VEGFR-2 [62]. Significant inhibition of tumor growth
and metastasis was observed in both melanoma and Lewis lung carcinoma metastasis murine
models [62]. Oral administration of mice with DNA vaccines encoding murine VEGFR-2
carried by attenuated Salmonella typhimurium could break the immune tolerance to VEGFR-2,
induce CTL response to VEGFR-2, inhibit tumor cell-induced neoangiogenesis, and suppress
the formation of spontaneous and experimental pulmonary metastases, with slight impact on
wounds healing and no influence on hematopoiesis and pregnancy [63]. Immunization of mice
with flk1-encoding mRNA-transfected DC could induce specific CTL response to VEGFR-2,
partially inhibit the tumor cell-induced neoangiogenesis, and suppress tumor growth and
metastasis in murine B16/F10.9 melanoma and MBT-2 bladder tumor models [64]. We studied
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the regulatory effects of IFN-γ on the differentiation and development of DC and found that
IFN-γ is an autocrine mediator for DC maturation [65]. IFN-γ gene transfection could promote
differentiation, development, and functional maturation of DC [66]. IFN-γ gene-modified DC
had increased capacity to induce Th1 type immune response, and intratumoral injection of
IFN-γ gene-modified DC in a murine model with pre-established B16 melanoma resulted in
the potentiation of the anti-tumor effect of DC [66]. On the other hand, it was demonstrated
that IFN-γ itself is also a negative regulator of neoangiogenesis [67]. In order to combine the
anti-angiogenic immunotherapy with the cytokine immunotherapy, we constructed recombi‐
nant plasmid expressing murine VEGFR-2 extracellular domain (sVEGFR-2) and IFN-γ fusion
protein, pcDNA3.1/sVEGFR-2-IFN-γ, and found that the fusion protein expressed by recombi‐
nant plasmid shared biological activities of both sVEGFR-2 and IFN-γ [68]. Immunization of
mice with murine sVEGFR-2-IFN-γ fusion gene-transfected DC could significantly augment
the CTL response to murine VEGFR-2 and pronouncedly inhibit tumor cell-induced angioge‐
nensis and tumor metastasis in comparison with murine sVEGFR2 gene-transfected DC [68].
In 2006, three CTL epitope candidates, designated as KDR1, KDR2 and KDR3, respectively,
from VEGFR-2 with high binding affinity to the H-2Db molecule were predicted by two
computer programs: Bimas and SYFPEITH [69]. Two of them, KDR2 and KDR3, were from
the extracellular domain; KDR1 was from the intracellular part of the receptor [69]. Immuni‐
zation of mice with KDR2 or KDR3 peptide in combination with murine GM-CSF and agonist
anti-mouse CD40 antibodies as adjuvant could break self-tolerance and induce specific
immune responses in C57BL/6 mice [69]. Furthermore, immunization of mice with these two
peptide epitopes elicited pronounced specific CTL responses to murine VEGFR-2, effectively
inhibited VEGF-induced angiogenesis, and suppressed tumor growth in MC38 murine colon
cancer model [69]. Similarly, the epitope peptides of human VEGFR-2 restricted by HLA-
A*0201 and HLA-A*2402 were also identified by analyzing the binding affinities to the
corresponding HLA molecules [70]. Antigen based on the epitope peptide with high binding
affinity to human HLA-A*0201 could successfully induce specific CTL response in vitro [70].
Furthermore, transgenic mice expressing HLA-A*0201, A2/Kb, were generated, and the
vascular endothelial cells in that mice could not only express human VEGFR-2 (KDR), but also
express human MHC class Ι molecules [70]. After inoculation of A2/Kb with HLA-A*0201
restricted VEGFR-2 epitope peptide, specific IFN-γ-expressed CTL was induced [70]. Immu‐
nization of tumor-bearing A2/Kb transgenic mice with VEGFR-2 epitope peptide could
markedly inhibit tumor-induced angiogenesis, hereby inhibiting tumor growth in MC38 colon
cancer and B16 melanoma models, and prolong survival of the tumor-bearing animals without
fatal adverse effects [70]. To further study whether specific CTL response to KDR can be elicited
in human or not, KDR epitope peptide vaccines were used to stimulate peripheral blood
mononuclear cells derived from 6 cancer patients in vitro, and CTLs specific for the peptide
epitope were successfully induced in all patients [70].
In comparison with the full-length protein, peptide vaccines like the aforementioned KDR
epitope peptides can be easily synthesized in high purity and are less expensive. Moreover,
immunization with such vaccines could avoid the potential dangers involving induction of an
infection by recombinant viruses or exposure to a latently allergenic exogenous protein.
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In 2009, Seavey, et al developed Listeria monocytogens based VEGFR-2 vaccines that encode the
peptide of VEGFR-2 extracellular domain fused to the first 441 residues of the microbial
adjuvant listeriolysin O (Lm-LLO-Flk-E1 and Lm-LLO-Flk-E2) and the peptide of VEGFR-2
intracellular domain that also fused to LLO (Lm-LLO-Flk-I1), respectively [71, 72]. Immuni‐
zation of the mice with the Listeria-based Flk1 vaccines elicited potent antitumor CTL respons‐
es. Lm-LLO-Flk-1 was able to eradicate some established Her-2/neu+ breast tumors, reduce
microvascular density in the remaining tumors, protect against tumor rechallenge and
experimental metastases, and induce epitope spreading to various regions of the tumor-
associated antigen Her-2/neu. Tumor eradication was found to be dependent on epitope
spreading to Her-2/neu and was not solely due to the reduction of tumor vasculature [71]. In
an autochthonous model for Her-2/neu+ breast cancer, theses vaccines could significantly
delay tumor onset, while tumors that grew out overtime accumulated mutations in the Her-2/
neu molecule near or within CTL epitopes [72]. Moreover, vaccine efficacy did not affect
normal wound healing nor have toxic side effects on pregnancy [71]. These data suggest that
an anti-angiogenesis vaccine can overcome tolerance to the host vasculature driving epitope
spreading to an endogenous tumor protein and drive active tumor regression.
Recently, a DNA vaccine (pSG.SS.Flk-1ECD.C3d3) encoding Flk-1 extracellular domain and the
complement fragment C3d fusion protein was constructed [73]. Vaccination of mice with
pSG.SS.Flk-1ECD.C3d3 could also elicit Flk-1 specific antibody response, leading to suppression
of angiogenesis and tumor growth in bladder translational cell carcinoma mouse model,
suggesting that C3d can be used as an adjuvant to enhance the immune response [73].
In 2010, Miyazawa, et al. [74] reported the results of phase I clinical trial combining of epitope
peptide for VEGFR-2 (VEGFR2-169) with gemcitabine for patients with advanced pancreatic
cancer. 18 HLA-A*2402-positive patients with metastatic and unresectable pancreatic cancer
were enrolled in the trial. Gemcitabine was administered at a dose of 1000 mg/m2 on days 1,
8, and 15 in a 28-day cycle. The VEGFR2-169 peptide was subcutaneously injected weekly in
a dose-escalation manner (doses of 0.5, 1, and 2 mg/body, six patients/one cohort). Safety and
immunological parameters were assessed. No severe adverse effect of grade 4 or higher was
observed. Of the 18 patients who completed at least one course of the treatment, 15 (83%)
developed immunological reactions at the injection sites. VEGFR2-169 specific CTLs were
induced in 11 (61%) of the 18 patients. The disease control rate was 67%, and the median overall
survival time was 8.7 months. This combination therapy for pancreatic cancer patients was
tolerable at all doses. Peptide-specific CTL could be induced by the VEGFR2-169 peptide
vaccine at a high rate, even in combination with gemcitabine. Therefore, they suggested that
the optimal dose for further clinical trials might be 2 mg/body or higher.
2.2.2. bFGF
Basic fibroblast growth factor (bFGF/FGF2) is an important proangiogenic factor, which is
secreted by tumor cells and macrophages or released by extracelluar matrix, and functions in
the autocrine or paracrine manner. FGF2 can upregulate the expression of several dominant
pro-angiogenic factors, such as VEGF [75], and activator of plasminogen [76], and inhibit
apoptosis of endothelial cells by bcl-2 pathway [77]. bFGF exerts its biological activities
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through its binding to high affinity receptor, fibroblast growth factor receptor-1 (FGFR1). It
was found that both peptide segments of synthetic human FGF2 heparin-binding structural
domain and receptor-binding structural domain could inhibit the in vitro proliferation of
human umbilical vein endothelial cells [39]. Immunization of mice with vaccine based on
heparin-binding structural domain peptide could induce production of anti-FGF2 specific
antibody, which could hamper the binding of FGF2 to heparin sulphate, and inhibit tumor-
induced angiogenesis in a gelatin sponge model and tumor growth in a tumor metastatic
model [39]. Surprisingly, despite an immune response toward FGF2, this modality of treatment
did not affect wound healing as shown by the fact that the treatment did not alter the mean
time of wound healing [78]. It also did not affect fertility, because the vaccinated females were
not impaired in their ability to become pregnant, to support the growth and development of
their embryos, and to deliver viable offspring when compared with control animals [78].
Furthermore, histological analyses did not reveal any alterations in organogenesis in these
offsprings [78]. Therefore, the authors concluded that although vaccination against FGF2
induced a specific FGF2 antibody response and inhibited angiogenesis and tumor develop‐
ment in a pathological setting, it did not adversely alter normal physiological events dependent
on FGF2.
2.2.3. EGFR
Epidermal growth factor receptor (EGFR), a membrane surface sensor with tyrosine kinase
activity, is widely distributed on the membrane of mammalian cells [79]. In the physiological
condition, EGFR exerts, through binding to ligands (epidermal growth factor, EGF), its
physiological activities in regulation of cell division, proliferation and differentiation [79].
Results from clinical studies show that high expression level of EGFR is frequently observed
in non-small cell lung cancer, and has been implicated in aggressive biological behavior of
tumor cells and poor prognosis of tumor patients [79]. Therefore, immunotherapy targeting
EGFR should be another attractive approach to the treatment of EGFR-positive tumors. In
murine tumor models with Lewis lung carcinoma and mammary cancer, immunization of
mice with DC pulsed with recombinant ectodomain of mouse EGFR (DC-edMER) inhibited
tumor angiogenesis, reduced tumor growth, and prolonged the survival of tumor-bearing
mice [80]. Spleen cells isolated from DC-edMER-immunized mice showed a high frequency of
EGFR-specific antibody-producing cells [80]. Anti-EGFR specific antibody was markedly
elevated in sera of immunized mice and was shown to be effective against tumor growth by
adoptive transfer [80]. Immunization with DC-edMER vaccine also elicited CTL responses [80].
Depletion of CD4+ T lymphocytes could completely abrogate the anti-tumor activity and
generation of EGFR-specific antibody responses, whereas depletion of CD8+ T lymphocytes
showed partial abrogation of the anti-tumor activity but antibody was still detected [80].
Furthermore, tumor-induced angiogenesis was suppressed in DC-edMER-immunized mice
or mice treated with antibody adoptive transfer [80]. These findings indicate that vaccination
with DC-edMER can induce both humoral and cellular anti-tumor immunity, and may suggest
novel strategies for the treatment of EGFR-positive tumors through the induction of active
immunity against EGFR [80].
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2.2.4. Legumain
Tumor associated macrophages (TAMs) are well known to play a very important role in tumor
angiogenesis and metastasis, as the abrogation of TAMs in tumor tissues effectively reduced
several pro-tumor growth and angiogenesis factors, such as VEGF, TGF-β, TNF-α and MMP-9
[81]. Thus, the suppression of TAMs in the tumor-microenvironment provides a novel strategy
to inhibit tumor growth and dissemination by remodeling the tumor’s stroma. Legumain is
an asparaginyl endopeptidase and a member of the C13 family of cystine proteases which was
found to be highly upregulated in many murine and human tumor tissues and, furthermore,
also overexpressed on TAMs in the murine tumor stroma, but absent or present at only very
low levels in all normal tissues from which such tumors arose [81-84]. Recently, several oral
minigene vaccines against murine MHC class I antigen epitopes of Legumain were constructed
based on the binding predictions for these MHC class I molecules by the HLA peptide binding
predictions program [85]. Expression vectors encoding these epitopes were designated as
pLegu-H-2Dd and pLegu-H-2Kd respectively [85]. Oral administration of those vaccines by
transforming them into attenuated Salmonella typhimurium (Dam–, AroA–) resulted in
significant suppression of angiogenesis in tumor tissues of D2F2 breast carcinoma in syngeneic
BALB/c mice [85]. The possible mechanism of angiogenic inhibition involved the induction of
a specific CTL response capable of killing Legumain positive cells, especially TAMs, which is
likely to be responsible for anti-tumor angiogenesis [85]. Generally, the anti-angiogenic effect
aided in the protection of BALB/c mice from lethal challenges with D2F2 breast tumor cells in
a prophylactic setting [85].
2.2.5. Endoglin (CD105)
Endoglin, a 95 kDa cell surface protein expressed as a homodimer, functions as an accessory
protein for kinase receptor complexes of the TGF-β superfamily and modulates TGF-β
signaling [8]. Expression of CD105 is correlated with vascular density and poor prognosis [8].
Endoglin is over-expressed on proliferating endothelial cells in the breast tumor neovascula‐
ture and thus offers a target for anti-angiogenic therapy [8]. It was reported that an oral murine
endoglin-encoding DNA vaccine carried by double attenuated Salmonella typhimurium
(dam–, AroA–) to a secondary lymphoid organ, i.e., Peyer’s patches, resulted in activation of
antigen-presenting dendritic cells, induction of immune responses mediated by CD8+ T cells
against endoglin-positive target cells, and suppression of angiogenesis and dissemination of
pulmonary metastases of D2F2 breast carcinoma cells presumably by eliminating proliferating
endothelial cells in the tumor vasculature, thus providing an promising strategy to therapies
for breast cancer [86]. More recently, Wood et al. [87] developed Listeria-based vaccines
directed against CD105, Lm-LLO-CD105A and Lm-LLO-CD105B. The region of CD105 in Lm-
LLO-CD105A vaccine contains at least three predicted H-2Kd epitopes, while the region of
CD105 in Lm-LLO-CD105B contains at least two predicted H-2Kd epitopes. Immunization of
the Listeria-based vaccines led to therapeutic responses against primary and metastatic tumors
in the 4T1-Luc and NT-2 mouse models of breast cancer. In a mouse model for autochthonous
Her-2/neu-driven breast cancer, Lm-LLO-CD105A vaccination prevented tumor incidence in
20% of mice by week 58 after birth while all control mice developed tumors by week 40. In
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comparison with previous Listeria-based vaccines (Lm-LLO-HMWMAA-C [88] and Lm-LLO-
FLK-I1 and Lm-LLO-FLK-E2 [71] ) targeting tumor vasculature, Lm-LLO-CD105A and Lm-
LLO-CD105B demonstrated equivalent or superior efficacy against two transplantable mouse
models of breast cancer. Mechanism analysis revealed that the anti-tumor therapeutic efficacy
of Listeria-based CD105 vaccines was mediated by epitope spreading to endogenous tumor
antigens and reduction in tumor vascularity [87]. These data suggest that CD105 therapeutic
vaccines are highly effective in stimulating anti-angiogenesis and anti-tumor immune
responses leading to therapeutic efficacy against primary and metastatic breast cancer.
2.2.6. Endothelial cell lysates-pulsed dendritic cells
Dendritic cells (DCs) are the most potent professional antigen-presenting cells, they play
crucial roles in the initiation of an immune response. DCs prepared from BALB/c mouse were
pulsed with lysates of autologous or xenogeneic endothelium, and their anti-tumor effects
were tested in two syngeneic models of colon cancer [89]. Immunization of endothelium lysates
pulsed DCs could induce a break in self tolerance against endothelial cells and mount both the
endothelium-specific CTL response and antibody response, leading to significant inhibition
of tumor angiogenesis and the growth of subcutaneous tumors as well as pulmonary meta‐
stases in mice. Furthermore, the decrease in the mean vascular density of tumors correlates
well with the extent of tumor inhibition [89]. Therefore, immunization of endothelium lysates
pulsed DCs is also an effective modality of anti-angiogenic active immunotherapy for cancers,
and should have important clinical implications for adjuvant cancer therapy.
2.2.7. Endothelial cell vaccine
In 2008, Okaji Y, et al. [90] reported a pilot phase I clinical study in which glutaraldehyde-
fixed  human  umbilical  vein  endothelial  cells  (HUVECs)  were  used  as  the  vaccine.  Six
patients  with  recurrent  malignant  brain  tumour  and  three  patients  with  metastatic
colorectal  cancer  were  given  intradermal  injections  of  5x107  HUVECs/dose,  first  month
weekly,  and then every  2  weeks  (in  total  230  vaccinations).  ELISA and flow cytometry
revealed immunoglobulin response against  HUVECs’  membrane antigens.  ELISPOT and
51Cr-release  cytotoxicity  assay  revealed  a  specific  cellular  immune  response  against
HUVECs, which were lysed in an effectors:targets ratio-dependent manner. Gadolinium-
contrasted  MRI  showed partial  or  complete  tumour  responses  in  three  malignant  brain
tumour patients. Except for a DTH-like skin reaction at the injection site, no adverse effect
of  vaccination  was  observed.  These  results  suggested  that  the  endothelial  vaccine  can
overcome peripheral  tolerance  of  self-angiogenic  antigens  in  clinical  settings,  and there‐
fore could be useful for adjuvant immunotherapy of cancer.
3. Concluding remarks
Recent research achievements have disclosed inspiring pragmatic perspectives of anti-
angiogenic active immunotherapy for cancers. In comparison with application of angiogenic
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inhibitors and angiogenic antibodies, anti-angiogenic active immunotherapy has its obvious
merits. Provided that a break of immunological tolerance to positive regulators of angiogenesis
is successfully induced, the long-lasting immune response to angiogenesis-related molecule
will be present in the body, hereby providing long-lasting inhibitory effects on angiogenesis.
Therefore, it is expected to be the more cost-effective strategy than angiogenic inhibitor or anti-
angiogenic antibody therapy where continuous use of the drugs is needed.
Here  we  divided  anti-angiogenic  active  immunotherapy  into  two  categories:  therapies
based  on  vaccination  with  xenogeneic  homologous  molecules  and  with  non-xenogeneic
homologous molecules related to angiogenesis. Presently, it is difficult to point out which
one is better for clinical application because most of the outcomes reported to date were
based on pre-clinical animal experiments. As VEGF-mediated signaling through its receptor
VEGFR-2 is the key rate-limiting step in tumor angiogenesis, and plays the most impor‐
tant role in neovascularization, development, and progression of various tumors [6], as well
as  human VEGFR2-169 peptide  vaccination could effectively  break peripheral  self  toler‐
ance against VEGFR-2 in patients with metastatic and unresectable pancreatic cancer [74],
anti-angiogenic  active  immunotherapy  targeting  VEGF  or  VEGFR-2  might  be  the  most
effective strategy among all  these therapies.  Moreover,  considering the potential  clinical
application  of  anti-angiogenic  immunotherapy  based  on  the  specific  antibodies  raised
against  a  variety  of  angiogenesis-associated  molecules  in  different  tumor  entities  like
glioma, renal cell  cancer,  and breast  cancer,  etc,  a promising clinical  application of anti-
angiogenic  active  immunotherapy  alone  or  in  combination  with  other  anti-tumor  strat‐
egies  could  be  expected.  However,  there  exist  as  well  caveats  and  deficiencies  in  this
strategy. Firstly, in the early phase of tumor growth when the tumor diameter is less than
2-3 mm, tumor cells  simply depend on passive diffusion rather than blood perfusion to
acquire enough oxygen and nutrition indispensable for growth. Therefore, anti-angiogen‐
ic  therapy  against  tumor  in  this  early  stage  might  be  ineffective  when  applied  alone.
Secondly,  although current  anti-angiogenic  active immunotherapy is  focused on specific
targets, potential adverse effects might include impairment of wound healing and menstru‐
al cycle. Furthermore, this approach has also limited application perspectives in children
with  cancers.  Therefore,  along  with  recent  developments  in  molecular  biology  and
immunology, future studies will focus on multiple approaches, such as series analysis of
gene expression to analyze the gene expression in normal endothelial cells and in prolifer‐
ative  endothelial  cells,  phage  display  technology  to  search  for  new  endothelial  cell
receptors, and proteomics to discover peptide segments or proteins regulating endothelial
cell growth. These approaches are expected to discover more tumor-specific endothelial cell
markers for the purpose of selecting specific targets for anti-angiogenic active immunother‐
apy. In addition, further studies are also required to optimize protocols how to construct
vaccines to effectively break self-tolerance and to induce efficient immune response. With
these issues being solved continuously, anti-angiogenic active immunotherapy for cancers
will become more applicable and effective.
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